ライフサイエンスコーパス: metaiodobenzylguanidine

1 Existing tracers such as (123)I-metaiodobenzylguanidine ((123)I-MIBG) and (11)C-(-)-meta

2 -(18)F-fluorodopamine ((18)F-DA) with (123)I-metaiodobenzylguanidine ((123)I-MIBG) and somatostatin r

3 on the in vivo myocardial kinetics of (123)I-metaiodobenzylguanidine ((123)I-MIBG) are scarce and hav

4 Scintigraphic imaging with (123)I-metaiodobenzylguanidine ((123)I-MIBG) has demonstrated e

5 Cardiac (123)I-metaiodobenzylguanidine ((123)I-mIBG) imaging improves p

6 lished the prognostic significance of (123)I-metaiodobenzylguanidine ((123)I-MIBG) imaging in heart f

7 (123)I-metaiodobenzylguanidine ((123)I-MIBG) imaging is a tool

8 ympathetic nerves can be evaluated by (123)I-metaiodobenzylguanidine ((123)I-MIBG) imaging.

9 ional 2-dimensional planar imaging of (123)I-metaiodobenzylguanidine ((123)I-mIBG) is not fully quant

10 I-MIBG; through November 1999) or iodine-123-metaiodobenzylguanidine ((123)I-MIBG) scan, urine catech

11 FDOPA PET were compared with those of (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy and (

12 to compare the diagnostic utility of (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy and (

13 Radioiodinated metaiodobenzylguanidine ((123)I-mIBG) scintigraphy is an

14 (123)I-metaiodobenzylguanidine ((123)I-MIBG) scintigraphy plays

15 A semiquantitative (123)I-metaiodobenzylguanidine ((123)I-MIBG) scoring method (th

16 e heart-to-mediastinum ratio (HMR) of (123)I-metaiodobenzylguanidine ((123)I-MIBG) uptake obtained us

17 uptake of (11)C-hydroxyephedrine and (123)I-metaiodobenzylguanidine ((123)I-MIBG) was examined by PE

18 adrenergic nerve activity assessed by (123)I-metaiodobenzylguanidine ((123)I-MIBG).

19 he radiolabeled norepinephrine analog (123)I-metaiodobenzylguanidine ((123)I-MIBG).

20 , a direct comparison of CLR 124 with (124)I-metaiodobenzylguanidine ((124)I-MIBG) in an MIBG-avid mo

21 ths included computed tomography, iodine-131-metaiodobenzylguanidine (131)I-MIBG; through November 19

22 f the targeted radiotherapeutic agent (131)I-metaiodobenzylguanidine ((131)I-MIBG) and tested the com

23 Iodine-131-metaiodobenzylguanidine ((131)I-MIBG) has been shown to

24 Targeted radiotherapy using (131)I-metaiodobenzylguanidine ((131)I-MIBG) has produced remis

25 Iodine-131-metaiodobenzylguanidine ((131)I-MIBG) provides targeted

26 Iodine-131-metaiodobenzylguanidine ((131)I-MIBG) selectively target

27 Reported experience with systemic (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy of neuroen

28 Adding (131)I-metaiodobenzylguanidine ((131)I-MIBG) to PRRT may be adv

29 f external-beam gamma-irradiation and (131)I-metaiodobenzylguanidine ((131)I-MIBG), a radiopharmaceut

30 High specific-activity (131)I-metaiodobenzylguanidine ([(131)I]MIBG) therapy is approv

31 High-dose administration of 131I-metaiodobenzylguanidine (131I-MIBG) continues to be a pr

32 py on response and toxicity after iodine-131-metaiodobenzylguanidine (131I-MIBG) treatment of patient

33 Six survivors developed an SMN after iodine-metaiodobenzylguanidine ((131I)MIBG) treatment.

34 and paragangliomas, including (131)I/(123)I-metaiodobenzylguanidine, 6-(18)F-fluoro-l-3,4-dihydroxyp

35 uctions of serial autoradiographs of [(125)I]metaiodobenzylguanidine and (99m)Tc-sestamibi.

36 ase studies included imaging with 131-iodine-metaiodobenzylguanidine and extensive bone marrow (BM) s

37 include the use of (177)Lu-DOTATATE, (131)I-metaiodobenzylguanidine, Bexxar, and Zevalin, clinically

38 iously shown that ex vivo counting of (131)I-metaiodobenzylguanidine can identify regional reductions

39 ve as (131)I-KX1, whereas cytoplasmic (125)I-metaiodobenzylguanidine demonstrated low biological effe

40 Iodine-123 metaiodobenzylguanidine (I-123 MIBG) and fluorescent mic

41 ceutical for high-risk neuroblastoma, (131)I-metaiodobenzylguanidine, is ineffective at targeting mic

42 y for uptake of the radiopharmaceutical 131I-metaiodobenzylguanidine (MIBG) (3).

43 oblastoma by correlating administered (131)I-metaiodobenzylguanidine (MIBG) activity to tumor and who

44 (3-(18)F-fluoro-propoxy)benzyl)guanidine), a metaiodobenzylguanidine (MIBG) analog, for the detection

45 (123)I-metaiodobenzylguanidine (MIBG) and (111)In-pentetrotide

46 (131)I-Metaiodobenzylguanidine (MIBG) and (90)Y-DOTA-D-Phe1-Tyr

47 athetic innervation and perfusion with [123I]metaiodobenzylguanidine (MIBG) and 201Tl, respectively.

48 Radiolabeled metaiodobenzylguanidine (MIBG) and somatostatin receptor

49 ined with CT, as well as imaging with (131)I-metaiodobenzylguanidine (MIBG) beginning late last centu

50 and preliminary antitumor activity of (131)I-metaiodobenzylguanidine (MIBG) combined with the anti-GD

51 o evaluate the efficacy and safety of (124)I-metaiodobenzylguanidine (MIBG) dosimetry-guided high-act

52 ter animals were injected with 37 MBq (125)I-metaiodobenzylguanidine (MIBG) followed in 3 h with 1,11

53 [(123)I]metaiodobenzylguanidine (MIBG) imaging and [(131)I]MIBG

54 mpathetic denervation assessed by 123-iodine metaiodobenzylguanidine (MIBG) imaging occurs early in d

55 mic reflex tests (CARTs), and cardiac (123)I-metaiodobenzylguanidine (MIBG) imaging.

56 Radiolabeled metaiodobenzylguanidine (mIBG) is a highly sensitive and

57 (131)I-metaiodobenzylguanidine (MIBG) is an active radiotherape

58 (131)I-metaiodobenzylguanidine (MIBG) is specifically taken up

59 dary endpoints were response rate and (123)I-metaiodobenzylguanidine (MIBG) response.

60 tional imaging modalities for neuroblastoma: metaiodobenzylguanidine (MIBG) scan for uptake by the no

61 The metaiodobenzylguanidine (MIBG) scan is one of the most s

62 ease status requires CT (or MRI), bone scan, metaiodobenzylguanidine (MIBG) scan, bone marrow tests,

63 ation that included iodine-123 or iodine-131 metaiodobenzylguanidine (MIBG) scan, bone scan, computed

64 ients underwent (18)F-DOPA PET/CT and (123)I-metaiodobenzylguanidine (MIBG) scanning plus SPECT/CT.

65 lid Tumors (RECIST) and iodine-123 ((123)I) -metaiodobenzylguanidine (MIBG) scans or [(18)F]fluorodeo

66 clear imaging techniques such as bone scans, metaiodobenzylguanidine (MIBG) scans, and (111)In-diethy

67 (INRC) recommend, but do not make mandatory, metaiodobenzylguanidine (MIBG) scans.

68 ients with disease evaluable only by [(123)I]metaiodobenzylguanidine (MIBG) scintigraphy and/or bone

69 The high sensitivity of metaiodobenzylguanidine (MIBG) scintigraphy for sympatho

70 (123/131)I-metaiodobenzylguanidine (MIBG) scintigraphy has shown a

71 linergic (parasympathetic) innervation, 123I-metaiodobenzylguanidine (MIBG) scintigraphy to measure c

72 [(131)I]Metaiodobenzylguanidine (MIBG) therapy in patients with

73 cells accumulated (123)I- or (124)I-labeled metaiodobenzylguanidine (MIBG) to high levels compared w

74 Metaiodobenzylguanidine (MIBG) was developed 18 yr ago f

75 Wistar rats: (201)Tl-chloride (TlCl), (123)I-metaiodobenzylguanidine (MIBG), (99m)Tc-sestamibi (MIBI)

76 ), iodine-123- (123I) and iodine-131 (131I) -metaiodobenzylguanidine (MIBG), 111In-pentetreotide, and

77 ely used theranostic agents targeting NET is metaiodobenzylguanidine (MIBG), a guanethidine analog of

78 diopharmaceuticals such as (18)F-FDG, (123)I-metaiodobenzylguanidine (MIBG), and (99m)Tc-tetrofosmin

79 Metaiodobenzylguanidine (MIBG), specifically taken up in

80 The analogue 131I-metaiodobenzylguanidine (MIBG), which is specifically ta

81 A PET analog of metaiodobenzylguanidine (MIBG)-(18)F-metafluorobenzylgua

82 acity to accumulate the noradrenaline analog metaiodobenzylguanidine (MIBG).

83 approved clinical grade radiolabeled probe, metaiodobenzylguanidine (MIBG).

84 important advances have occurred using 131I metaiodobenzylguanidine (MIBG).

85 the currently available radiotracers (e.g., metaiodobenzylguanidine [MIBG]).

86 Three-dimensional reconstructed CMR/(123)I-metaiodobenzylguanidine models were coregistered for fur

87 Magnetic resonance imaging, metaiodobenzylguanidine scan, single-photon emission tom

88 eochromocytomas are best diagnosed with 131I-metaiodobenzylguanidine scanning.

89 Postinduction metaiodobenzylguanidine scans showed normal radiotracer

90 Nuclear imaging approaches, such as(123) I-metaiodobenzylguanidine scintigraphy and 6-[(18) F]fluor

91 Cardiac (123)I-metaiodobenzylguanidine scintigraphy was conducted in a

92 atients evaluable for response by iodine-123 metaiodobenzylguanidine score had objective responses (f

93 lier signs of cardiotoxicity comprise (123)I-metaiodobenzylguanidine SPECT to visualize sympathetic i

94 linium enhancement cardiac MRI (CMR), (123)I-metaiodobenzylguanidine SPECT, and high-resolution bipol

95 cted in PD with (18)F-dopamine PET or (123)I-metaiodobenzylguanidine SPECT.

96 rine, (11)C-metahydroxyephedrine, and (123)I-metaiodobenzylguanidine that measure cardiac sympathetic

97 xtravasation of a therapeutic dose of (131)I-metaiodobenzylguanidine that produced a radiation burn t

98 PECT/CT imaging using the radiotracer (123)I-metaiodobenzylguanidine was performed in 33 recovered CO